A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators

Journal of Alzheimer's Disease

Volumn 28, Issue 4, 2012, Pages 809-822

  Borghys, Herman ^a   Tuefferd, Marianne ^a   Van Broeck, Bianca ^a   Clessens, Ellen ^a   Dillen, Lieve ^a   Cools, Willy ^a   Vinken, Petra ^a   Straetemans, Roel ^a   De Ridder, Filip ^a   Gijsen, Harrie ^a   Mercken, Marc ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; amyloid ; dog; gene expression; liver; secretase

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 37; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; BILIRUBIN; E 2012; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JNJ 42601572; SEMAGACESTAT; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL DOG; FEMALE; LIQUID CHROMATOGRAPHY; LIVER BIOPSY; LIVER FUNCTION; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 84858059332     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111475     Document Type: Article

References (51)

1. Jalbert JJ, Daiello LA, Lapane KL (2008) Dementia of the Alzheimer type. Epidemiol Rev 30, 15-34.
2. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
4. Murphy MP, LeVine H 3rd (2010) Alzheimer's disease and the β-amyloid peptide. J Alzheimers Dis 19, 311-323.
5. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid beta-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100, 330-335. (Pubitemid 36078074)
6. Cole SL, Vassar R (2008) The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiology. J Biol Chem 283, 29621-29625.
7. Wolfe MS (2008) Gamma-secretase inhibition and modulation for Alzheimer's disease. Curr Alzheimer Res 5, 158-164.
8. De Strooper B, Vassar R, Golde T (2010) The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6, 99-107.
9. Epis R, Gardoni F, Marcello E, Genazzani A, Canonico PL, Di Luca M (2010) Searching for new animal models of Alzheimer's disease. Eur J Pharmacol 626, 57-63.
10. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, Wagner SL (2010) Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769-780.
11. El Mouedden M, Vandermeeren M, Meert T, Mercken M (2006) Reduction of Aβ levels in the sprague dawley rat after oral administration of the functional γ-secretase inhibitor, DAPT: A novel non-transgenic model for Aβ production inhibitors. Curr Pharm Des 12, 671-676.
12. Hook G, Hook VY, Kindy M (2007) Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapreutics. Biol Chem 388, 979-983. (Pubitemid 47258539)
13. Cotman CW, Head E (2008) The canine (dog) model of human aging and disease: Dietary, environmental and immunotherapy approaches. J Alzheimers Dis 15, 685-707.
14. Studzinski CM, Araujo JA, Milgram NW (2005) The canine model of human cognitive aging and dementia: Pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 29, 489-498. (Pubitemid 40417601)
15. Sarasa L, Gallego C, Monleon I, Olvera A, Canudas J, Montanes M, Pesini P, Sarasa M (2010) Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. Neuroscience 171, 1901-1101.
16. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K (2010) Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 21, 1005-1012.
17. Shimomura N, Sato N, Kaneko T, Takaishi M, Wakasugi K, Yoshikawa S, Nishikawa Y, Nakamura T, Hukuyama T (2007) Process for the preparation of cinnamamide derivative. WO 2007058305, http://www.wipo.int/patentscope/search/ en/detail.jsf?docId=WO2007058305.
18. Gijsen HJM, Bischoff FP, Zhuang W, Van Brandt SFA, Surkyn M, Zaja M, Berthelot DJC, De Cleyn MAJ, Macdonald GJ, Oehlrich D (2009) Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators. WO 2010094647, http://www.wipo.int/patentscope/ search/en/detail.jsf?docId=WO2010094647.
19. Koenig TM, Audia JE, Mitchell D, McDaniel SL, Buccilli LA, Engel GL, Aikins JA (2002) Preparation of lactam derivative useful for inhibiting β-amyloid peptide release and/or its synthesis. WO 2002040451, http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2002040451.
20. Starrett JE, Gillman KW, Olson RE (2010) A novel alpha-(n-sulfonamido) acetamide compound as an inhibitor of beta amyloid peptide production. WO 2010107435, http://www.wipo.int/patentscope/search/en/detail.jsf?docId= WO2010107435.
21. Wilsson-Rahmberg M, Olovson SG, Forshult E (1998) Method for long-term cerebrospinal fluid collection in the conscious dog. J Invest Surg 11, 207-214. (Pubitemid 28425423)
22. Dillen L, Cools W, Vereyken L, Timmerman P (2011) A screening UPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. Bioanalysis 3, 45-55.
23. Mercken M, Brepoels E, De Jongh M, Laenen W, Raeymakers P, Geerts H (2000) Specific ELISA systems for the detection of endogenous human and rodent Aβ40 and Aβ42. Neurobiol Aging 21, S41.
24. Gabrielsson J, Weiner D (2002) Phamacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press; 3rd edition.
25. Pinheiro JC, Bates DM (2000) Mixed-effects models in S and S-Plus, Springer-Verlag, New York.
26. R: A Language and Environment for Statistical, R Development Core Team, R Foundation for Statistical Computing (2011), Vienna, Austria, http://www. R-project.org.
27. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F (2005) Evolving Gene/Transcript Definitions Significantly Alter the Interpretation of Gene Chip Data. Nucl Acid Res 33, e175.
28. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5, R80.
29. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
30. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat App Genet Mol Biol 3, No. 1, Article 3.
31. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57, 289-300.
32. Raghavan N, De Bondt AM, Talloen W, Moechars D, Gohlmann HW, Amaratunga D (2007) The high-level similarity of some disparate gene expression measures. Bioinformatics 23, 3032-3038. (Pubitemid 350162868)
33. Hyslop PA, May PC, Audia JE, Calligaro DO, McMillian CL, Garner CO, Cramer JW, Gitter BD, Porter WJ, Nissen JS, Mabry TE, Bender MH (2004) Reduction in A-beta (1-40) and A-beta (1-42) in CSF and plasma in the beagle dog following acute oral dosing of the gamma secretase inhibitor, LY-450139. Neurobiol Aging 25, 147.
34. Davies S, Pandian R, Bolos J, Castaner R (2009) Semagacestat. Drugs Future 34, 613-617.
35. Gillman KW, Starrett JA, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA,Williams R, Meredith JE Jr, Burton CR, Barten DM, Toyn JH, Roberts SB, Lentz KA, Houston JG, Zaczek R, Albright CF, Decicco CP, Macor JE, Olson RE (2010) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. ACS Med Chem Lett 1, 120-124.
36. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase II safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer's disease. Arch Neurol 65, 1031-1038.
37. Nagase H, Koh CS, Nakayama K (2011) γ-secretase-regulated signaling pathways, such as Notch signaling, mediate the differentiation of hematopoietic stem cells, development of the immune system, and peripheral immune responses. Curr Stem Cell Res Ther 6, 131-141.
38. Sawitza I, Kordes C, Reister S, Häussinger D (2009) The niche of stellate cells within rat liver. Hepatology 50, 1617-1624.
39. Cho IJ, Kim YW, Han CY, Kim EH, Anderson RA, Lee YS, Lee CH, Hwang SJ, Kim SG (2010) E-cadherin antagonizes transforming growth factor β1 gene induction in hepatic stellate cells by inhibiting RhoA-dependent Smad3 phosphorylation. Hepatology 52, 2053-2064.
40. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KEG, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB (2006) Concentration-dependent modulation of Amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139. J Pharmacol Exp Therap 319, 924-933.
41. Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H (2010) Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener 5, 2.
42. Petterson M, Kauffmann GW, Am Ende CW, Patel NC, Stiff C, Tran TP, Johnson DS (2011) Novel γ-secretase modulators: A review of patents from 2008 to 2010. Expert Opin Ther Patents 21, 205-226.
43. Oehlrich D, Berthelot DJ, Gijsen HJ (2011) Gamma-secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 54, 669-698.
44. Geier A, Wagner M, Dietrich CG, Trauner M (2006) Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 1773, 283-308. (Pubitemid 46275063)
45. Anderson N, Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60, 311-357.
46. Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y (2008) Physicochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18, 4872-4875.
47. Blomme EAG, Yang Y, Waring JF (2009) Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett 186, 22-31.
48. Buck WR, Waring JF, Blomme EA (2008) Use of traditional end points and gene dysregulation to understand mechanisms of toxicity: Toxicogenomics in mechanistic toxicology. Methods Mol Biol 460, 23-44.
49. Magold AI, Cacquevel M, Fraering PC (2009) Gene expression profiling in cells with enhanced β-secretase activity. PloS One 4, e6952.
50. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) γ-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment. J Neurosci 29, 13042-13052.
51. De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease. EMBO Rep 8, 141-146.